ReviewWorld journal of oncology2025
Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.
Review in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic nutritional index and the survival of patients with hepatocellular carcinoma on immune checkpoint inhibitors: a meta-analysis.BMC cancer · 2025Pooled it
- Mendelian randomization analysis reveals no causal association between non-alcoholic fatty liver disease and hepatocellular carcinoma: implications for lipid metabolomics and shared pathophysiological mechanisms.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma that is composed of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Given its low incidence, there is no standardized treatment protocol or systemic regimens. With the development of immune checkpoint inhibitors (ICIs), one of the immunotherapies that modulate the immune system by restoring antitumor immune response, studies have shown promising results for the use of ICI as systemic therapy for advanced solid tumors, including liver cancers. Moreover, prospective clinical studies displayed favorable outcomes of the use of ICIs in HCC and biliary tract cancers. Here, we review the recent evidence in application and comparison of ICIs for HCC, CCA, and cHCC-CCA as well as the future direction of systemic therapy for cHCC-CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.